Actinium Pharmaceuticals (Delaware) (ATNM) vs MindWalk (HYFT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Actinium Pharmaceuticals (Delaware) (ATNM) has outperformed MindWalk (HYFT) over the past year, losing 21.1% versus a loss of 59.0%. Over five years, ATNM leads with a -85.6% price change compared with -89.3% for HYFT. Actinium Pharmaceuticals (Delaware) is the larger company by market cap ($33.0 million vs $32.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATNM | HYFT |
|---|---|---|
| Share price | $1.05 | $0.6844 |
| Market cap | $33.01M | $32.56M |
| 1-day change | -1.87% | -14.27% |
| YTD return | -22.79% | -62.40% |
| 1-year return | -21.05% | -59.02% |
| 5-year return | -85.60% | -89.34% |
| P/E ratio (TTM) | 2.44 | — |
| EPS (TTM) | $0.43 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $90.00K | — |
| Net income (latest FY) | $-33.89M | — |
| Operating margin | -40274.44% | — |
| Net margin | -37652.22% | — |
| 52-week high | $1.72 | $2.99 |
| 52-week low | $0.735 | $0.64 |
| Distance from 52-week high | -38.95% | -77.11% |
| Analyst consensus | none | none |
| Avg. price target upside | +242.86% | +532.67% |
| Average volume | 193.83K | 257.86K |
| Shares outstanding | 31.44M | 47.57M |
| Employees | 27 | 74 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ATNM has outperformed HYFT by 38.0 percentage points over the past year.
About Actinium Pharmaceuticals (Delaware)
ATNM stock →Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
About MindWalk
HYFT stock →MindWalk Holdings Corp. operates as a bio-native AI company.
Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees
ATNM vs HYFT FAQ
Which is bigger, Actinium Pharmaceuticals (Delaware) or MindWalk?
Actinium Pharmaceuticals (Delaware) (ATNM) is larger, with a market capitalization of $33.01M compared with $32.56M for MindWalk (HYFT).
Which stock has performed better over the past year, ATNM or HYFT?
ATNM returned -21.05% over the past 12 months, compared with -59.02% for HYFT (price return, excluding dividends). Past performance does not predict future results.
Are Actinium Pharmaceuticals (Delaware) and MindWalk in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.